NASDAQ : CTKB
Cytek Biosciences, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 6.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 818.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 796.80M |
| Enterprise Value | 561.25M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 129.98M |
| Shares Outstanding | 129.98M |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | +0.59% |
| Owned by Insiders (%) | 8.48% |
| Owned by Institutions (%) | 50.97% |
| Float | 102.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.85 |
| Forward PS | 3.67 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.48 |
| Quick Ratio | 3.71 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -152.08 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -23.04% |
| Return on Assets (ROA) | -6.31% |
| Return on Invested Capital (ROIC) | -52.92% |
| Return on Capital Employed (ROCE) | -13.09% |
| Weighted Average Cost of Capital (WACC) | 10.32% |
| Revenue Per Employee | $303,092 |
| Profits Per Employee | -$118,150 |
| Employee Count | 682 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.93 |
Taxes
| Measure | Value |
|---|
| Income Tax | 39.76M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.16 |
| 52-Week Price Change | +52.87% |
| 50-Day Moving Average | 5.28 |
| 200-Day Moving Average | 4.65 |
| Relative Strength Index (RSI) | 65.63 |
| Average Volume (20 Days) | 1,426,675 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.41M |
| Short Previous Month | 5.22M |
| Short % of Shares Out | 3.39% |
| Short % of Float | 4.28% |
| Short Ratio (days to cover) | 2.67 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 206.71M |
| Gross Profit | 107.23M |
| Operating Income | -47.45M |
| Pretax Income | -40.82M |
| Net Income | -80.58M |
| EBITDA | -39.76M |
| EBIT | -47.45M |
| Loss Per Share | -$0.63 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 262.00M |
| Total Debt | 26.46M |
| Net Cash | 235.54M |
| Net Cash Per Share | $1.81 |
| Equity (Book Value) | 321.95M |
| Book Value Per Share | 2.48 |
| Working Capital | 293.60M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.04M |
| Capital Expenditures | -6.04M |
| Depreciation & Amortization | 7.69M |
| Net Borrowing | 3.05M |
| Free Cash Flow | -12.08M |
| FCF Per Share | -$0.09 |
Margins
| Measure | Value |
|---|
| Gross Margin | 51.87% |
| Operating Margin | -22.95% |
| Pretax Margin | -19.75% |
| Profit Margin | -38.98% |
| EBITDA Margin | -19.24% |
| EBIT Margin | -22.95% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.28% |
| Shareholder Yield | 0.28% |
| Earnings Yield | -10.26% |
| FCF Yield | -1.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.17 |
| Price Target Difference | 0.60% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 6.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.15 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |